Last reviewed · How we verify
NCT06045585
JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma
EARLY_PHASE1 trial testing infusion of JY231 injection in Relapsed or Refractory B-cell Lymphoma in 20 participants. Status unknown.
31 August 2025
Quick facts
| Lead sponsor | Guangdong Second Provincial General Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 18 August 2023 |
| Primary completion | 31 August 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- infusion of JY231 injection — full drug profile →
Conditions studied
- Relapsed or Refractory B-cell Lymphoma — all drugs for Relapsed or Refractory B-cell Lymphoma →
Sponsor
Guangdong Second Provincial General Hospital
Who can join
Adults 18 to 75, any sex, with Relapsed or Refractory B-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B-cell lymphoma
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06045585
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Relapsed or Refractory B-cell Lymphoma
Currently open trials in the same condition.
- NCT05806580 — Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma · Phase 4 · recruiting
Other Guangdong Second Provincial General Hospital trials
Trials by the same sponsor.
- NCT07537257 — VEN+IDAC vs IDAC in AML · Phase 2, PHASE3 · enrolling by invitation
- NCT07517510 — HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL). · Phase 2 · enrolling by invitation
- NCT06834555 — Mobile Phone Thermal Imaging Assessment of Incompetent Perforator Veins · NA · not yet recruiting
- NCT06758609 — To Assess the Effectiveness and Safety of Catheter-based Focal Intracranial Hypothermia Combined with Endovascular Reper · NA · recruiting
- NCT06298266 — To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06045585 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangdong Second Provincial General Hospital
- Last refreshed: 21 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06045585.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing